JP MORGAN/CALL/VERTEX PHARMACEUTICALS/355/0.1/17.01.25

JP MORGAN/CALL/VERTEX PHARMACEUTICALS/355/0.1/17.01.25 Share Price

DE000JL07U88

Market Closed - Börse Stuttgart 03:06:43 21/06/2024 pm IST
12.64 ^EUR	+5.16%

Current month	+23.44%
1 month	+21.07%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart JP MORGAN/CALL/VERTEX PHARMACEUTICALS/355/0.1/17.01.25

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Vertex Pharmaceuticals Discloses 'Positive' Data From Phase 1/2 Trial of VX-880 to Treat Type 1 Diabetes	22/06	MT
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions	22/06	BU
Vertex Pharmaceuticals, Inc. Announces Positive Results from Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes	22/06	CI
Vertex Pharmaceuticals Has Pricing Accord for Cystic Fibrosis Drugs With UK National Health Service	20/06	MT

More news

Quotes 5-day view

Date	Price	Change
21/24/21	12.64	+5.16%
20/24/20	12.02	-0.74%
19/24/19	12.11	-5.24%
18/24/18	12.78	-5.75%
17/24/17	13.56	+2.81%

Delayed Quote Börse Stuttgart

Last update June 21, 2024 at 03:06 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	J.P. Morgan
WKN	JL07U8
ISIN	DE000JL07U88
Date issued	12/04/2023
Strike	355 $
Maturity	17/01/2025 (209 Days)
Parity	10 : 1
Emission price	4.88 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	13.59 €
Lowest since issue	5.08 €
Delta	0.89x
Omega	3.143
Premium	4.08x
Gearing	3.53x
Moneyness	1.320
Difference Strike	-113.7 $
Difference Strike %	-32.03%
Spread	0.3 €
Spread %	2.39%
Theoretical value	12.42
Implied Volatility	37.51 %
Total Loss Probability	17.20 %
Intrinsic value	10.63
Present value	1.787
Break even	487.82 €
Theta	-0.07x
Vega	0.06x
Rho	0.15x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

468.7 USD

Average target price

463.4 USD

Spread / Average Target

-1.13%

Consensus